Background: To compare the cognitive profile of older patients with schizophrenia to those with other neuropsychiatric disorders assessed in a hospital-based memory clinic.

Methods: Demographic, clinical, and cognitive data of all patients referred to the memory clinic at the Centre for Addiction and Mental Health between April 1, 2006 and August 15, 2008 were reviewed. We then identified four groups of older patients with: (1) late-life schizophrenia (LLS) and no dementia or depression (DEP); (2) Alzheimer's disease (AD); (3) DEP and no dementia or LLS; (4) normal cognition (NC) and no DEP or LLS.

Results: The four groups did not differ in demographic data except that patients with AD were about 12 years older than those with LLS. However, they differed on cognitive tests even after controlling for age. Patients with LLS were impaired on most cognitive tests in comparison with patients with NC but not on recalling newly learned verbal information at a short delay. They experienced equivalent performance on learning new verbal information in comparison with patients with AD, but better performance on all other tests of memory, including the ability to recall newly learned verbal information. Finally, they were more impaired than patients with DEP in overall memory.

Conclusions: Patients with LLS have a different cognitive profile than patients with AD or DEP. Particularly, memory impairment in LLS seems to be more pronounced in learning than recall. These findings suggest that cognitive and psychosocial interventions designed to compensate for learning deficits may be beneficial in LLS.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2853579PMC
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0010151PLOS

Publication Analysis

Top Keywords

cognitive profile
12
patients
10
older patients
8
data patients
8
cognitive tests
8
patients lls
8
comparison patients
8
newly learned
8
learned verbal
8
patients dep
8

Similar Publications

Empathy is multifaceted, involving sharing and understanding the emotional and mental states of others. This study investigated the factor structure of the English-language version of the Empathy Quotient for Children (EQ-C; Auyeung et al., 2009), an empathy measure previously well-validated only as a global scale.

View Article and Find Full Text PDF

Objectives: Although research has shown that higher levels of within-person variability across cognitive tasks (dispersion) are associated with cognitive decline in clinical samples, little is known about dispersion in comparatively younger, non-clinical, and national samples. A better understanding of dispersion is needed to elucidate for whom and under what circumstances dispersion can be used as a reliable indicator of cognitive health.

Method: We used data from the Midlife in the United States Study (MIDUS; n = 2,229; Mage = 56 years, range = 33-83; 56% female) to: (a) characterize dispersion and its cross-sectional correlates in a non-clinical, adult lifespan sample and (b) examine changes in dispersion over time to determine for whom changes in dispersion may reflect better or worse cognitive aging.

View Article and Find Full Text PDF

An Updated Bio-Behavioral Profile of the Flinders Sensitive Line Rat: Reviewing the Findings of the Past Decade.

Pharmacol Res Perspect

February 2025

Faculty of Health Sciences, Centre of Excellence for Pharmaceutical Sciences, North-West University, Potchefstroom, South Africa.

The Flinders sensitive line (FSL) rat is an accepted rodent model for depression that presents with strong face, construct, and predictive validity, thereby making it suitable to investigate novel antidepressant mechanisms. Despite the translatability of this model, available literature on this model has not been reviewed for more than ten years. The PubMed, ScienceDirect and Web of Science databases were searched for relevant articles between 2013 and 2024, with keywords relating to the Flinders line rat, and all findings relevant to treatment naïve animals, included.

View Article and Find Full Text PDF

Biomarkers.

Alzheimers Dement

December 2024

Department of Neurology & Innovation Center for Neurological Disorders, Xuanwu Hospital, Capital Medical University, National Center for Neurological Disorders, Beijing, Beijing, China.

Background: It is challenging to distinguish which subcortical ischemic vascular disease (SIVD) patients will present with cognitive impairment. A blood-based biomarker to distinguish SIVD patients with cognitive impairment would be superior to neuropsychological measures and neuroimaging measures in terms of cost, time, and feasibility for repeated measures. Metabolomics profiling studies could help identify blood-based biomarkers for SIVD patients with cognitive impairment.

View Article and Find Full Text PDF

Background: This study aims at applying the AT(N) classification to a cohort of patients with Alzheimer's disease (AD) and related disorders, and to investigate how many cases would be eligible for the emerging disease-modifying treatments.

Method: We conducted a retrospective evaluation of 429 patients referred to the Memory Center of IRCCS San Raffaele Hospital in Milan. Patients underwent clinical/neuropsychological assessments, lumbar puncture, structural brain imaging, and positron emission tomography (FDG-PET).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!